Evidence Explorer · MS-N276 · Supportive physical care · Appraised November 8, 2026
A 171-participant multicenter double-blind randomized trial reported short-term pain reduction from transcutaneous electrical nerve stimulation without increased analgesic use. The unusually large percentage-change estimates, short assessment windows and limited independent replication keep certainty modest.
Evidence at a glance
- Population: 171 people with pancreatic-cancer abdominal or back pain; 87 TENS and 84 control.
- Intervention: transcutaneous electrical nerve stimulation added to ongoing care.
- Comparator: blinded control treatment.
- Primary result: the reported between-group difference in mean percent NRS change was 50.0 points immediately after treatment and 22.5 points after the three-week cycle.
- Evidence label: positive single-trial evidence; independent confirmation needed.
What was studied
The trial was registered as NCT03331055 and also assessed analgesic consumption, constipation and appetite. The abstract reports pain benefit without increased analgesic use.
The report’s percentage-change presentation is difficult to translate into an absolute, clinically meaningful pain difference. Device parameters, sham credibility, missing data and adverse-event details require full-text appraisal before clinical application.
What this evidence cannot establish
This study does not establish opioid replacement, durable benefit beyond the treatment cycle, benefit for all cancer pain mechanisms or safety with every implanted device. Pain relief does not indicate tumor response.
Safety and practical context
Cancer pain can signal obstruction, fracture, infection, thrombosis or other urgent problems. TENS should not delay diagnostic assessment or prescribed analgesia. Review pacemakers and implanted stimulators, seizure history, skin integrity, sensation and electrode placement with the care team.
Questions for the care team
- What is causing the pain, and is TENS appropriate for that mechanism?
- What device settings, schedule and sham-controlled evidence apply?
- How will pain, function, sleep and analgesic use be tracked, and when should it be stopped?
Sources and identifiers
- Multicenter randomized double-blind trial — PMID 33592831
Funding and conflicts: The study reported support from Guangdong provincial and national specialty grants and declared no conflicts of interest.
Source access and dates: Original PubMed records and available full texts were checked November 8, 2026. Last literature search November 8, 2026.
Educational evidence summary, not individualized medical advice. Supportive-care outcomes do not demonstrate tumor response, recurrence prevention or longer survival.
